Coronavirus SARS‐CoV‐2: filtering fact from fiction in the infodemic

Q&A with virologist Professor Urs Greber
Coronavirus SARS‐CoV‐2: filtering fact from fiction in the infodemic
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

As the severe acute respiratory syndrome (SARS) coronavirus 2 (SARS‐CoV‐2) continues to spread across the world, and the associated lung disease COVID‐19 remains difficult to treat, information from media and private communication flows at high speed, often through unfiltered channels. Much of this information is speculative, as it derives from preliminary and inconclusive studies, and creates confusion as well as anxiety. This phenomenon was recently labelled as ‘infodemic’ by the World Health Organization.

We interviewed Dr. Urs Greber, Professor of Molecular Cell Biology and Principal Investigator in Virology at the Department of Molecular Life Sciences of the University of Zurich, Switzerland, to answer some of the most controversial questions about SARS‐CoV‐2 and set the facts straight.

What is the origin of this virus?

Why is it more infectious than most coronaviruses?

Why do children hardly develop severe symptoms?

Is the severity of COVID-19 increasing over time?

How stable is coronavirus on particular surfaces?

What therapeutic approaches are being explored to defeat COVID-19?

Read the full article to find out more.

 

First published in FEBS Letters, 4 April 2020

How to cite this interview:

Ruffell, D. (2020), Coronavirus SARS‐CoV‐2: filtering fact from fiction in the infodemic. FEBS Lett. doi:10.1002/1873-3468.13784

 

Join the FEBS Network today

Joining the FEBS Network’s molecular life sciences community enables you to access special content on the site, present your profile, 'follow' contributors, 'comment' on and 'like' content, post your own content, and set up a tailored email digest for updates.